Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Morgan Stanley

Eaton Vance Worldwide Health Sciences Fund Eaton Vance Worldwide Health Sciences Fund Class A (ETHSX)

Ticker ETHSX · · Holdings as of May 31, 2026

Expense ratio
1.18%$118/yr per $10k
5-yr return
+5.3%annualized
1-yr return
−1.9%as of Dec 2024
Net assets
$757.9Mall share classes
Holdings
42

Bottom line

Is ETHSX a good fund? The bottom line

ETHSX is a share class of Eaton Vance Worldwide Health Sciences Fund, an actively managed health care sector mutual fund from Morgan Stanley.

Annual fees run 1.18% — about $118 a year on every $10,000 invested, more expensive than 68% of health care sector funds we track.

It returned −1.9% over one year, +5.3% a year over five years, +6.4% a year over ten (as of Dec 31, 2024, per its prospectus).

With $758 million in net assets and 42 holdings, its largest position is Eli Lilly & Co (12.5%) and the top 10 make up 58.6% of the portfolio.

This share class carries a front-end sales charge of up to 5.25%; a no-load class or ETF alternative can avoid it.

The closest lower-cost alternative we found is XLV (0.08%, 63% top-holdings overlap).

What to watch

  • Concentrated: top 10 holdings are 58.6% of assets
  • Front-end sales load up to 5.25%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What ETHSX invests in

The Funds investment objective is to seek long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies.

The Fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities (primarily common stocks) of companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies (health sciences companies) (the 80% Policy). A company will be considered to be a health sciences company if, at the time of investment: (i) the company is classified as a member of the Global Industry Classification Standard (GICS) health care sector; (ii) the company is a component of the S&P 500 Health Care Index or the MSCI World Health Care Index; or (iii) 50% or more of the companys sales, earnings or assets will arise from or will be dedicated to the application of…

From the fund's prospectus (filed Dec 23, 2025).

ETHSX performance

Fund calendar-year total returns, 2015–2024 2015: +8.4%; 2016: −14.9%; 2017: +16.2%; 2018: +6.0%; 2019: +26.0%; 2020: +13.0%; 2021: +22.1%; 2022: −9.4%; 2023: +5.7%; 2024: +3.5% +8% 2015 −15% 2016 +16% 2017 +6% 2018 +26% 2019 +13% 2020 +22% 2021 −9% 2022 +6% 2023 +4% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
ETHSX−1.9%+5.3%+6.4%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full ETHSX performance history →

What ETHSX costs

On a $10,000 investment, ETHSX's 1.18% expense ratio costs about $118 a year. The prospectus estimates $1,911 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full ETHSX fee table →

ETHSX top 10 holdings

#Holding% of fund
1Eli Lilly & Co12.47%
2AbbVie Inc6.46%
3Johnson & Johnson6.45%
4AstraZeneca PLC6.24%
5UnitedHealth Group Inc5.49%
6Roche Holding AG5.44%
7Merck & Co Inc5.08%
8Bristol-Myers Squibb Co4.25%
9Vertex Pharmaceuticals Inc3.38%
10Gilead Sciences Inc3.34%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 58.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to ETHSX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%63% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%63% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%62% Compare
iSharesIXJ iShares Global Healthcare ETF0.38%74% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%63% Compare
SchwabSWHFX Schwab Health Care Fund0.8%69% Compare

More funds like ETHSX →

ETHSX FAQ

What is the expense ratio of ETHSX?
ETHSX's expense ratio is 1.18%, which works out to about $118 a year for every $10,000 invested. The prospectus estimates total costs of $1,911 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ETHSX a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 58.6% of assets; front-end sales load up to 5.25%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does ETHSX hold?
ETHSX's largest holdings are Eli Lilly & Co (12.5%), AbbVie Inc (6.5%), Johnson & Johnson (6.4%), AstraZeneca PLC (6.2%), UnitedHealth Group Inc (5.5%). It holds 42 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is ETHSX's 5-year return?
ETHSX returned +5.3% a year over the five years ending Dec 31, 2024, and +6.4% a year over ten years. Past performance does not guarantee future results.
Does ETHSX have a sales load?
Yes. ETHSX has a maximum front-end sales charge of 5.25%.
What is a cheaper alternative to ETHSX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 63% with ETHSX and charges 0.08%.
Who manages ETHSX?
ETHSX is offered by Morgan Stanley through Eaton Vance Growth Trust.